Arvinas is a biotechnology company dedicated to improving the lives of patients with debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras (PROTACs) that harness the body's natural protein disposal system to selectively degrade disease-causing proteins. Arvinas has achieved a major milestone with FDA approval of the first-ever PROTAC protein degrader therapy and is progressing multiple investigational drugs through clinical development, including ARV-102 for neurodegenerative diseases, ARV-806 for KRAS G12D mutated cancers, ARV-393 for non-Hodgkin Lymphoma, ARV-027 for spinal bulbar muscular atrophy, and vepdegestrant for ER+ breast cancer. The company has entered strategic partnerships, including a global license agreement with Novartis for ARV-766 for prostate cancer treatment.
Beta · Sourced from candidate reports
Be the first to share your experience with Arvinas.
Your reply helps other candidates know what to expect.
